The potent TGF-β antagonist Norrin as a new drug for the treatment of fibrotic diseases and cancer
Human Norrin protein has been originally identified in the art as being a crucial
factor in the development of Norrie disease and is thought to be primarily involved in the Wnt signaling pathway. In the present invention, Norrin is being identified for the first time as a potent TGF-β antagonist/inhibitor. Furthermore, it has surprisingly been found herein that Norrin can be used in the treatment of diseases associated with an increased TGF-β activity level, such as fibrotic diseases and proliferative diseases, resp. cancer.
Further Information: PDF
Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0
Contact
Peer Biskup
Media Contact
All latest news from the category: Technology Offerings
Newest articles
High-energy-density aqueous battery based on halogen multi-electron transfer
Traditional non-aqueous lithium-ion batteries have a high energy density, but their safety is compromised due to the flammable organic electrolytes they utilize. Aqueous batteries use water as the solvent for…
First-ever combined heart pump and pig kidney transplant
…gives new hope to patient with terminal illness. Surgeons at NYU Langone Health performed the first-ever combined mechanical heart pump and gene-edited pig kidney transplant surgery in a 54-year-old woman…
Biophysics: Testing how well biomarkers work
LMU researchers have developed a method to determine how reliably target proteins can be labeled using super-resolution fluorescence microscopy. Modern microscopy techniques make it possible to examine the inner workings…
